- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01169298
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphoma
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Fukuoka, Japan, 811-1395
- National Kyusyu Cancer Center
-
Kagoshima, Japan, 890-0064
- Imamura Bun-in Hospital
-
Kumamoto, Japan, 860-8556
- Kumamoto University Hospital
-
Nagasaki, Japan, 852-8501
- Nagasaki University Hospital
-
Nagoya, Japan, 466-8650
- Nagoya Daini Red Cross Hospital
-
Tokyo, Japan, 104-0045
- National Cancer Center Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject must understand and voluntarily sign the written informed consent;
- Aged 20 years or older;
Subject have a documented diagnosis of either:
- Acute-, lymphoma-, or unfavorable chronic-type ATL or
- Peripheral T-cell Lymphomaperipheral (PTCL)
- Subject have received ≥1 prior anti-cancer therapy, have achieved stable disease (SD) or better on their immediately prior therapy and have relapsed or progressed at the time of obtaining signed informed consent;
- Subject have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2 at enrollment;
Exclusion Criteria:
- Natural Killer cell lymphoma (NK-cell lymphoma);
- T-cell leukemia;
Cutaneous T-cell lymphoma (CTCL) including;
- Mycosis fungoides
- Sezary syndrome
- CD30-positive lympho-proliferative disorders
- Cutaneous gamma/delta T-cell lymphoma
- Subject have a history of central nervous system (CNS) involvement or present with CNS symptoms, and are diagnosed with CNS lymphoma by cerebrospinal fluid (CSF) cytology examination, head CT scan or brain MRI during the screening;
- Are pregnant or lactating;
Subject have uncontrolled inter-current illness including:
- Uncontrolled diabetes mellitus
- Chronic congestive heart failure (NYHA Class III or IV)
- Unstable angina pectoris, angioplasty, stenting, or myocardial infarction (within 6 months before starting the study drug)
- Clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia
- Other uncontrolled diseases
- Exhibit grade 4 neurological disorders;
- Subject have a history or complication of deep vein thrombosis or pulmonary embolism within 6 months before the start of study treatment;
- Develop active tuberculous disease, herpes simplex, systemic mycosis, or other active infections requiring systemic administration of antibiotics, antiviral agents, or antifungal drugs;
- Are tested positive for HBs antigen, anti-HCV antibody, or anti-HIV antibody;
- Subjects have a history or complication for which the investigator or subinvestigator deems them inappropriate for this study, or have serious diseases or mental illness that is likely to be aggravated by participation in this study;
- Subjects have a history of allogeneic stem cell transplantation;
- Subjects have received autologous stem cell transplantation within 12 weeks (84 days) of the start of study treatment;
- Have previously used lenalidomide;
- Have a history of desquamating (bullous) rash while taking thalidomide;
- Have received any investigational drugs (unapproved drugs in Japan) within 4 weeks (28 days) of the start of study medication;
- Have received chemotherapeutic agents or immunomodulators for the treatment of ATL or PTCL within 4 weeks (28 days) of the start of study treatment;
- Have received radiotherapy within 4 weeks (28 days) of the start of study treatment;
Have a history or complication of another malignant tumor than ATL or PTCL (excluding malignant tumors below), unless the patients have been free of the disease for 5 years or longer;
- Cutaneous basal cell carcinoma or squamous cell carcinoma
- Cervical carcinoma in situ
- An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b)
Have had any of the following abnormal measurements at screening performed within 1 week (7 days) prior to the enrollment;
- Neutrophil count: < 1,200/µL (1.2 x 109/L)
- Platelet count: < 75,000/µL (75 x 109/L)
- Serum aspartate aminotransferase/ Serum glutamic oxaloacetic transaminase (AST/SGOT) or Alanine transaminase/Serum Glutamic Pyruvate Transaminase (ALT/SGPT): > 3 times the Upper Limit of Normal (ULN)
- Bilirubin level: > 1.5 times of the ULN
- Creatinine clearance: < 60 mL/min
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lenalidomide
Lenalidomide: 25mg daily on day1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort) or 35 mg daily of each 28 days (3rd cohort)
|
Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The safety of lenalidomide evaluated based on the severity of adverse events and their causality
Time Frame: Up to 2.5 years
|
The safety of lenalidomide evaluated based on the severity of adverse events and their causality
|
Up to 2.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response
Time Frame: Up to 2.5 years
|
The response of ATL patient to lenalidomide will be evaluated according to the criteria proposed by the International Consensus Meeting. The response of PTCL will be assessed by the Japan Clinical Oncology Group (JCOG) response criteria that have been established by the Lymphoma Study Group of the JCOG based on criteria of Cheson et al.in the Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas |
Up to 2.5 years
|
PK-Time to Maximum Plasma Concentration (Tmax)
Time Frame: Day 8 of Cycle 1
|
PK-Time to Maximum Plasma Concentration (Tmax)
|
Day 8 of Cycle 1
|
PK-Apparent Total Body Clearance (CL/F)
Time Frame: Day 8 of Cycle 1
|
PK-Apparent Total Body Clearance (CL/F)
|
Day 8 of Cycle 1
|
PK-Apparent Volume of Distribution (Vz/F)
Time Frame: Day 8 of Cycle 1
|
PK-Apparent Volume of Distribution (Vz/F)
|
Day 8 of Cycle 1
|
PK-Terminal half-life (T1/2)
Time Frame: Day 8 of Cycle 1
|
PK-Terminal half-life (T1/2)
|
Day 8 of Cycle 1
|
PK-Area under the Plasma concentration time curve (AUC)
Time Frame: Day 8 of Cycle 1
|
PK-Area under the Plasma concentration time curve (AUC)
|
Day 8 of Cycle 1
|
Accumulation ratio (Cmax)
Time Frame: Day 8 of Cycle 1
|
Accumulation ratio (Cmax)
|
Day 8 of Cycle 1
|
Accumulation ratio (AUCτ)
Time Frame: Day 8 of Cycle 1
|
Accumulation ratio (AUCτ)
|
Day 8 of Cycle 1
|
PK-Maximum Concentration in Plasma (Cmax)
Time Frame: Day 8 of cycle 1
|
PK-Maximum Concentration in Plasma (Cmax)
|
Day 8 of cycle 1
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Hiroya Asou, MD, Celgene KK
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Leukemia, Lymphoid
- Lymphoma
- Leukemia
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Leukemia, T-Cell
- Leukemia-Lymphoma, Adult T-Cell
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
Other Study ID Numbers
- CC-5013-ATLL-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral T-cell Lymphoma
-
The First Affiliated Hospital of Xiamen UniversityThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsRecruitingPeripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell LymphomaChina
-
National Cancer Centre, SingaporeMerck Sharp & Dohme LLC; National Medical Research Council (NMRC), SingaporeNot yet recruitingRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaSingapore
-
The Lymphoma Academic Research OrganisationCompletedRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaFrance, Belgium
-
Millennium Pharmaceuticals, Inc.CompletedRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaUnited States, France, Italy, Poland, United Kingdom, Belgium, Germany, Spain, Belarus, Israel, Portugal, Bulgaria, Turkey, Canada, New Zealand, Peru, Brazil, Russian Federation, Chile, Puerto Rico, Australia, Austria, Hungary, Nether... and more
-
University of Alabama at BirminghamTerminatedAnaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T-cell Lymphomas | Adult T-cell Leukemia | Adult T-cell Lymphoma | Peripheral T-cell Lymphoma Unspecified | T/Null Cell Systemic Type | Cutaneous t-Cell Lymphoma With Nodal/Visceral DiseaseUnited States
-
Legend Biotech USA IncActive, not recruitingT-Cell Lymphoma | Peripheral T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Recurrent | Peripheral T-Cell Lymphoma RecurrentUnited States
-
Karyopharm Therapeutics IncTerminatedCutaneous T-cell Lymphoma (CTCL) | Peripheral T-cell Lymphoma (PTCL)Australia, Singapore
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
-
OnxeoTerminatedNon-Hodgkin's Lymphoma | Cutaneous T-Cell Lymphoma | Peripheral T-Cell LymphomaUnited States, Germany, Israel, France, Thailand
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingAngioimmunoblastic T-cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma | Follicular T-Cell Lymphoma | Nodal Peripheral T-Cell Lymphoma...United States
Clinical Trials on Lenalidomide
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedMyelodysplastic SyndromeUnited States
-
Grupo Español de Linfomas y Transplante Autólogo...Celgene Corporation; Dynamic Science S.L.; Thermo Fisher Scientific, IncCompleted
-
Celgene CorporationICON Clinical ResearchCompletedMyelodysplastic SyndromesGermany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
-
Boston VA Research Institute, Inc.Celgene Corporation; Edward Hines Jr. VA Hospital; Michael E. DeBakey VA Medical... and other collaboratorsCompletedMultiple MyelomaUnited States
-
Swiss Group for Clinical Cancer ResearchTerminatedLymphomaSwitzerland, Norway, Sweden
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaboratorsTerminatedWaldenstrom's MacroglobulinemiaUnited States
-
University Hospital, ToulouseCelgene Corporation; Janssen-Cilag Ltd.Completed
-
CelgeneCompletedRelapsed or Refractory Chronic Lymphocytic LeukemiaUnited States, Canada, United Kingdom, France, Germany, Spain, Italy, Sweden
-
Groupe Francophone des MyelodysplasiesUnknownMyelodysplastic SyndromesFrance